Tn Hitchhiker Vaccines for High-Affinity Antibody Production and Targeted Cancer Cell Binding

Area of Science:

• Immunology
• Glycobiology
• Vaccine Development

Background:

• Effective cancer vaccines require robust humoral immune responses against tumor-associated antigens.
• The Tn antigen, a truncated O-glycan overexpressed in carcinomas, is a promising target for immunotherapy.

Purpose of the Study:

• To evaluate the antibody specificity induced by the Tn-DSPE-PEG-2000 amphiphilic vaccine in mice.
• To gain initial insights into the vaccine's cellular processing, including lysosomal escape and antigen delivery.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) to assess antibody recognition of Tn antigen components.
• Confocal microscopy to evaluate specific binding of anti-Tn antibodies to cancer cells (MCF-7) versus non-cancer cells (HEK293).
• Flow cytometry and surface plasmon resonance (SPR) to validate antibody reactivity and quantify antibody-antigen affinity.

Main Results:

• The Tn-DSPE-PEG-2000 vaccine undergoes lysosomal escape, enabling cytoplasmic antigen delivery for enhanced antigen presentation.
• ELISA confirmed that all components of the Tn antigen construct are crucial for antibody recognition.
• Confocal microscopy and flow cytometry demonstrated high specificity of anti-Tn antibodies for Tn-positive cancer cells.
• SPR analysis quantified high-affinity interactions between anti-Tn antibodies and the Tn antigen.

Conclusions:

• The Tn-DSPE-PEG-2000 vaccine elicits a highly specific antibody response against the Tn antigen.
• The structural integrity of the Tn antigen is essential for effective recognition by the generated antibodies.